Peer-influenced content. Sources you trust. No registration required. This is HCN.

TheBodyProIDWeek 2022 Study Bites: What’s New in HIV Antiretroviral Therapy

A trio of posters look at clinical effectiveness fostemsavir for multidrug-resistant patients, real-world efficacy of the dolutegravir/lamivudine combination as a switch strategy, and a newer drug in the pipeline, islatravir prodrug BRII-732.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form